2019
DOI: 10.7150/jca.31184
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Backgrounds: High blood glucose or hyperglycemia is an established risk factor for the development and progression of cancer at many sites, whereas data on the relevance between low blood glucose or hypoglycemia and cancer survival are lacking.Aims: We aimed to assess the shape of risk trajectory between preoperative fasting glucose and postoperative digestive cancer-specific mortality in Chinese.Methods: In total, 6865 patients who underwent radical surgery for esophageal cancer (n=2535), gastric cancer (n=30… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 32 publications
1
1
0
Order By: Relevance
“…Similar findings are also reported in other relatively large studies (15)(16)(17). However, some studies fail to demonstrate a significant association (18) or for instance propose a U-shaped risk trajectory for the concentrations (19). Still, the majority indicate that blood glucose concentration may impact survival.…”
Section: The Clinical Implications: the Impact Of The Metabolic Supply Lines On Patient Survival And On The Development Of Metastasessupporting
confidence: 87%
“…Similar findings are also reported in other relatively large studies (15)(16)(17). However, some studies fail to demonstrate a significant association (18) or for instance propose a U-shaped risk trajectory for the concentrations (19). Still, the majority indicate that blood glucose concentration may impact survival.…”
Section: The Clinical Implications: the Impact Of The Metabolic Supply Lines On Patient Survival And On The Development Of Metastasessupporting
confidence: 87%
“…Total 3012 patients with gastric cancer who received radical resection of primary gastric cancer for the first time, underwent no presurgical and postsurgical chemotherapy/radiotherapy, and were consecutively recruited from January 2000 to December 2010, with the latest follow‐up ended on December 31, 2015, were eligible for inclusion, as previously described. 11 , 13 , 14 , 15 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 The reason for us to exclude patients with presurgical and postsurgical chemotherapy/radiotherapy is due to its significant impact on survival outcomes.…”
Section: Methodsmentioning
confidence: 99%